TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03804853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitiation
Description: This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
Study: NCT02679300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise group (control group)
Study: NCT02507531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeXsys Embolization System
Description: Woven metallic mesh placed in aneurysm fundus
Study: NCT02658253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: 2.56 µg of GLA content
Study: NCT01261299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon-14-labeled carboplatin
Description: Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
Study: NCT03699722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Activities
Description: Format:Video; discussion; information handouts; facilitated referral

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Format: Information handouts
Study: NCT03743571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure therapy
Description: participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: exposure therapy
Description: participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
Study: NCT04721431

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric assessment
Description: MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric assessment
Description: MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric assessment
Description: MyotonPro device is vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.These stimulations induce damped natural oscillations in the tissue and the device records these oscillations using an accelerometer. Muscle tone, elasticity, and stiffness are calculated separately by the device
Study: NCT01347905

Intervention type: OTHER
Intervention: Stable-isotope techniques
Description: Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
Study: NCT00397982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo tumor resection
Study: NCT03026712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real dual tDCS + Robotic Arm Therapy
Description: Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS + Robotic Arm Therapy
Description: SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks.
Study: NCT02958839

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
Study: NCT00405665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Group 2 will receive the inactive treatment followed by the active treatment.
Study: NCT05191199

Intervention type: DIAGNOSTIC_TEST
Intervention: Penile Duplex Study
Description: A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Penile Duplex Study
Description: A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
Study: NCT04312152

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Vitamin B complex
Description: Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
Study: NCT01710839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg Ranibizumab
Description: intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg Ranibizumab
Description: intravitreal injections

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Pan Retinal Photocoagulation
Description: Targeted Pan Retinal Photocoagulation based on wide field angiography
Study: NCT02821975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive computer training
Description: COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
Study: NCT01641731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk
Description: Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached.
Study: NCT02707562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 1
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 2
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 3
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
Study: NCT02658253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: 2.56 µg of GLA content

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: 2.56 µg of GLA content

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: 2.56 µg of GLA content

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: 0.85 mg og Aluminium content

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: 0.85 mg og Aluminium content

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: 0.85 mg og Aluminium content

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: 0.85 mg og Aluminium content

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Na cl

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Na cl
Study: NCT02548143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa (Recombinant)
Description: LR769
Study: NCT05244694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Priming dose then a constant infusion at 40 mU•m-2•min-1
Study: NCT01134250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2 in combination with paclitaxel
Description: Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT03856411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study: NCT02015728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor biology testing
Description: Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide.
Study: NCT03804853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitiation
Description: This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
Study: NCT01910415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin hydrochloride
Study: NCT04400565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery group
Description: The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
Study: NCT03538366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor FMT
Description: Fecal transplant from unrelated, healthy donors using enemas
Study: NCT02399774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leboride
Description: 1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leboride
Description: 1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
Study: NCT04706481

Intervention type: PROCEDURE
Intervention: Specimen Collection
Description: Specimens obtained from surgical, phlebotomy or other non-invasive procedure

Intervention type: PROCEDURE
Intervention: Specimen Collection
Description: Specimens obtained from surgical, phlebotomy or other non-invasive procedure
Study: NCT02378324

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening without fee
Description: All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
Study: NCT02309008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028
Description: Participants will receive PAC-14028 cream applied topically once a day for 9 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Participants will receive vehicle cream applied topically once a day for 9 days
Study: NCT03257033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Chemotherapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenovoCath
Description: Intra-arterial catheter
Study: NCT02602522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shandong Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shandong Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sichuan Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sichuan Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
Study: NCT02150278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
Study: NCT02212041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disposable electronic cigarettes
Description: Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained.
Study: NCT00849368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine / Allopurinol
Description: Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets
Study: NCT01914666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study: NCT03271879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin at a dose of 10 mg/day
Description: Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin at a dose of 10 mg/day
Description: Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
Study: NCT00966706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given systemically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given systemically
Study: NCT03251573

Intervention type: OTHER
Intervention: cognitive impairment
Description: one are of patients were exposed to cognitive impairment
Study: NCT03765736

Intervention type: OTHER
Intervention: Genetic Testing
Description: Undergo genetic testing
Study: NCT00423306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darinaparsin
Description: 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months